Certolizumab pegol for induction of remission in Crohn's disease.

ABSTRACT:

Background

Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal tract, and immune response modulation is the main treatment strategy to induce remission in active CD. Certolizumab pegol (CZP) is a tumor necrosis factor-alfa (TNF-α) inhibitor which regulates impaired immune response.

Objectives

The primary objectives were to evaluate the efficacy and safety of CZP for the induction of remission in CD.

Search methods

We searched MEDLINE, Embase, CENTRAL, the Cochrane IBD group specialized register, trials registers and other sources from inception to 28 January 2019. Moreover, we contacted the pharmaceutical company that manufactures CZP.

Selection criteria

We included randomized controlled trials comparing CZP with placebo or no treatme

SUBMITTER: Yamazaki H 

PROVIDER: S-EPMC6718195 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature